蒲江濤,唐小軍,胡智,吳云飛,何開明,李淵,戴天陽(yáng)
(西南醫(yī)科大學(xué)附屬醫(yī)院 胸心外科,四川 瀘州 646000)
·論著·
SPOCK1通過(guò)mTOR-s6K信號(hào)通路誘導(dǎo)肺癌細(xì)胞增殖、侵襲和遷移
蒲江濤,唐小軍,胡智,吳云飛,何開明,李淵,戴天陽(yáng)
(西南醫(yī)科大學(xué)附屬醫(yī)院 胸心外科,四川 瀘州 646000)
目的探討SPOCK1在肺癌組織的表達(dá)及對(duì)肺癌細(xì)胞增殖、侵襲和遷移的影響。方法肺癌細(xì)胞株A549、H3255按照轉(zhuǎn)染類型分為RNA干擾組和對(duì)照組(NC組),采用小干擾RNA(siRNA)技術(shù)抑制肺癌A549、H3255細(xì)胞SPOCK1的表達(dá),MTT增殖實(shí)驗(yàn)檢測(cè)細(xì)胞增殖能力,集落形成實(shí)驗(yàn)檢測(cè)細(xì)胞集落形成能力,劃痕實(shí)驗(yàn)檢測(cè)細(xì)胞遷移能力,Transwell實(shí)驗(yàn)檢測(cè)細(xì)胞侵襲能力,RT- PCR和Western blotting檢測(cè)mTOR- s6K信號(hào)通路相關(guān)mRNA和蛋白的表達(dá)水平。結(jié)果在肺癌A549、H3255細(xì)胞中,siSPOCK1組細(xì)胞增殖率、集落形成數(shù)、侵襲細(xì)胞數(shù)、劃痕愈合率明顯低于NC組(P<0.05)。在SPOCK1敲除的A549細(xì)胞中,siSPOCK1組和NC組G0/G1期細(xì)胞數(shù)分別為66.5%和54.3%,兩組間比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05);在H3255細(xì)胞中,siSPOCK1組和NC組G0/G1期細(xì)胞數(shù)分別為70.2%和55.7%,兩組間比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。A549、H3255細(xì)胞中,與NC組比較,siSPOCK1組mTOR、s6K mRNA表達(dá)水平明顯下降,組間比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05);siSPOCK1組p- mTOR、p- s6K蛋白相對(duì)表達(dá)水平明顯低于NC組,兩組間比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論降低SPOCK1表達(dá)能夠抑制肺癌細(xì)胞增殖、侵襲和遷移能力,其作用機(jī)制可能與mTOR- s6K信號(hào)通路有關(guān)。
SPOCK1; 肺癌; 增殖; 侵襲; 遷移; mTOR- s6K信號(hào)通路
肺癌是世界范圍內(nèi)高發(fā)的惡性腫瘤,其發(fā)病率和死亡率呈逐年上升趨勢(shì)。盡管部分基因突變的病例能夠通過(guò)靶向藥物干預(yù)治療,然而突變基因僅存在于部分肺腺癌中。另外各種環(huán)境因素、表觀遺傳等的作用也直接影響肺癌細(xì)胞的生存、侵襲[1- 2]。因此探討肺癌增殖、侵襲和轉(zhuǎn)移的作用機(jī)制,發(fā)現(xiàn)潛在的治療靶點(diǎn),對(duì)開發(fā)新的靶向分子藥物具有重要的指導(dǎo)意義。細(xì)胞外基質(zhì)蛋白多糖SPOCK1(sparc/osteonectin,cwcv,and kazal- like domains proteoglycan 1,SPOCK1)是新發(fā)現(xiàn)的鈣離子結(jié)合蛋白多糖家族的成員之一。在多種惡性腫瘤的增殖、侵襲中發(fā)揮著重要作用。目前關(guān)于SPOCK1在肺癌細(xì)胞中的生物學(xué)功能及其介導(dǎo)的作用機(jī)制目前報(bào)道較少。鑒于此,本研究首先采用免疫印跡法(Western blotting)、免疫組化法檢測(cè)肺癌組織SPOCK1表達(dá),分析SPOCK1與肺癌預(yù)后的關(guān)系;再采用小干擾RNA(small interfering RNA,siRNA)技術(shù)抑制肺癌細(xì)胞SPOCK1表達(dá),分析其對(duì)細(xì)胞增殖、侵襲和轉(zhuǎn)移的作用及可能的作用機(jī)制,旨在為肺癌的治療、預(yù)防、診斷提供新的作用靶點(diǎn)。
肺癌細(xì)胞株A549、H3255購(gòu)自美國(guó)菌種保藏中心(American Type Culture Collection,ATCC),細(xì)胞接種于DMEM培養(yǎng)基(Gibco公司),含10%胎牛血清、100 U·ml-1青霉素和100 mg·ml-1鏈霉素,在培養(yǎng)箱中37 ℃、5%CO2培養(yǎng)。每隔2~3 d更換1次培養(yǎng)基,每隔3 d傳代1次,選擇傳3代以上細(xì)胞用于后續(xù)實(shí)驗(yàn)。
RIPA裂解液、胰蛋白酶、二甲基亞砜(DMSO)、胎牛血清、BCA蛋白濃度測(cè)定試劑盒購(gòu)自廣州碧云天生物技術(shù)研究所。Trizol試劑、RT- PCR反應(yīng)試劑盒、脂質(zhì)體Lipofectamine 2000TM購(gòu)自美國(guó)Invitrogen公司。SPOCK1干擾RNA序列委托南京科佰生物科技有限公司合成設(shè)計(jì),SPOCK1- siRNA序列:5’- GUAAUGAGGAGGGCUAUUA- 3’,陰性對(duì)照(SPOCK1- NC)序列:5’- CGUAUGCGCGUACUCUAAUTT- 3’。RNA提取試劑、SYBRPremix ExTaqⅡ試劑盒購(gòu)自寶生物工程(大連)有限公司;Transwell小室、Matrigel人工基底膜購(gòu)自美國(guó)BD公司。抗SPOCK1(1∶100,博士德生物工程有限公司,武漢)、抗mTOR(1∶500,碧云天,海門)、抗p- mTOR(1∶200,碧云天,海門)、抗s6K[1∶100,生工生物工程(上海)股份有限公司,上海]、抗p- s6K[1∶100,生工生物工程(上海)股份有限公司,上海]、抗GAPDH(1∶200,博士德生物工程有限公司,武漢),聚烯酰胺、PVDF膜、十二烷基硫酸鈉購(gòu)自美國(guó)Sigma公司。
1.3.1 細(xì)胞瞬時(shí)轉(zhuǎn)染 取培養(yǎng)3代以上生長(zhǎng)狀態(tài)良好的細(xì)胞,接種于6孔板中,37 ℃、5%CO2孵育24 h后進(jìn)行轉(zhuǎn)染。A549細(xì)胞按照轉(zhuǎn)染類型分為RNA干擾(A549- siSPOCK1)組、陰性對(duì)照(A549- NC)組;H3255細(xì)胞按照轉(zhuǎn)染類型分為H3255- siSPOCK1組和H3255- NC組。siSPOCK1組向每孔中加入5 μl Lipofectamine 2000、5 μl RNA干擾序列和500 μl不含血清的培養(yǎng)基,NC組每孔中加入5 μl Lipofectamine 2000、5 μl RNA陰性對(duì)照序列和500 μl不含血清的培養(yǎng)基。37 ℃、5%CO2條件下孵育,待轉(zhuǎn)染24 h后采用Western blotting檢測(cè)各組細(xì)胞SPOCK1蛋白表達(dá),篩選出轉(zhuǎn)染效率最高的細(xì)胞株,擴(kuò)大培養(yǎng),用于后續(xù)實(shí)驗(yàn)。
1.3.2 MTT檢測(cè)細(xì)胞增殖能力 取對(duì)數(shù)生長(zhǎng)期細(xì)胞,接種于96孔板(1×105個(gè)·孔-1),每組設(shè)3個(gè)復(fù)孔,37 ℃、5%CO2、飽和濕度(95%)下培養(yǎng)。檢測(cè)前4 h 向每孔中加入MTT試劑(20 μl·孔-1)繼續(xù)孵育24 h,終止培養(yǎng),1 000×g離心15 min,棄去上清液,每孔中加入150 μl DMSO溶解結(jié)晶物,室溫下振蕩15 min,置于酶標(biāo)儀上檢測(cè)570 nm處吸光度值(A值),以評(píng)價(jià)細(xì)胞生長(zhǎng)能力。
1.3.3 細(xì)胞集落培養(yǎng)試驗(yàn) 收集轉(zhuǎn)染24 h后細(xì)胞,0.25%胰酶消化,1 000×g離心5 min,細(xì)胞重懸。將細(xì)胞接種于培養(yǎng)皿的板底,置于恒溫培養(yǎng)箱中連續(xù)培養(yǎng)1周,直至肉眼可見細(xì)胞集落,PBS沖洗,10%甲醛固定,結(jié)晶紫染色,對(duì)集落進(jìn)行計(jì)數(shù)。
1.3.4 Transwell小室實(shí)驗(yàn)檢測(cè)細(xì)胞侵襲能力 用不含血清的培養(yǎng)基將轉(zhuǎn)染后細(xì)胞濃度調(diào)整為1.0×105個(gè)·ml-1,Transwell上室每孔接種150 μl細(xì)胞,下室加入600 μl含有20%胎牛血清的RPMI- 1640培養(yǎng)基作為趨化劑,37 ℃培養(yǎng)48 h,輕輕拭去表面非侵襲性細(xì)胞,4%多聚甲醛固定,結(jié)晶紫染色10 min,100倍顯微鏡下統(tǒng)計(jì)穿透濾膜的細(xì)胞數(shù)。
1.3.5 劃痕實(shí)驗(yàn)檢測(cè)細(xì)胞遷移能力 將細(xì)胞接種于6孔板,Marker筆在培養(yǎng)板后均勻劃間距為0.5 cm的橫線,每孔中鋪1×105個(gè)細(xì)胞,細(xì)胞融合度≥80%時(shí)用無(wú)菌移液槍槍頭在單層細(xì)胞沿底部劃出“一”字劃痕,PBS沖洗3次,培養(yǎng)24 h后在顯微鏡下測(cè)量劃痕的寬度,并計(jì)算劃痕愈合率。劃痕愈合率=(初始劃痕寬度-不同時(shí)間點(diǎn)劃痕寬度)/初始劃痕寬度×100%。
1.3.6 流式細(xì)胞儀檢測(cè)細(xì)胞周期 轉(zhuǎn)染48 h后,取對(duì)數(shù)生長(zhǎng)期細(xì)胞,加入70%乙醇固定,置于4 ℃冰箱保存待檢。上機(jī)檢測(cè)前用PBS沖洗3次,37 ℃ RNA酶(1 g·L-1)消化20 min,碘化丙啶染色30 min,流式細(xì)胞儀檢測(cè)各組細(xì)胞的周期。
1.3.7 實(shí)時(shí)熒光定量PCR(RT- PCR)檢測(cè)SPOCK1、mTOR、s6K mRNA表達(dá) 收集生長(zhǎng)狀態(tài)良好的細(xì)胞,加入1 ml Trizol裂解液,冰浴上靜置10 min。紫外分光光度計(jì)測(cè)定260 nm和280 nm處吸光度值,A260/A280>2.0表示RNA純度合格。取2 μl總RNA進(jìn)行逆轉(zhuǎn)錄:2 μl總RNA中加入8 μl無(wú)核酸酶水和2 μl RT Primer,85 ℃反應(yīng)5 min后置于冰浴3 min。再向上述12 μl混合物中加入RT buffer 3 μl、dNTP 0.5 μl、RNase 1 μl、ddH2O 8 μl,反應(yīng)條件:37 ℃ 60 min,85 ℃ 5 min。取5 μl逆轉(zhuǎn)錄產(chǎn)物作為模板,利用SYBRPremix ExTaqⅡ試劑盒進(jìn)行RT- PCR,GAPDH作為內(nèi)參,反應(yīng)條件:95 ℃預(yù)變性30 s,95 ℃變性10 s,60 ℃延伸40 s,35個(gè)循環(huán)后74 ℃延伸5 min。引物委托上海捷瑞生物工程有限公司設(shè)計(jì)合成,SPOCK1上游:5′- ATGCCTGTAACAAAGAAGCCCC- 3′,下游:5′- CACACAGTTGCCCCCGTTTTTAC- 3′;mTOR SPOCK1上游:5′- AAGGGGGCTATGGAAAGGCAA- 3′,下游:5′- AATCCACGATGAAGGGATGCT- 3′; s6K SPOCK1上游:5′- GAACCTCAGGGCAAGATGCT- 3′,下游:5′- CTGGTTTCCTCATTCCGGCT- 3′; GAPDH上游:5′- ATGTCGTGGAGTCTACTGGC- 3′,下游:5′- TGACCTTGCCCACAGCCTTG- 3′。目的基因表達(dá)量用2- ΔΔct表示,每個(gè)樣本均檢測(cè)3次。
1.3.8 Western blotting檢測(cè)SPOCK1、mTOR、S6K蛋白表達(dá) 取對(duì)數(shù)生長(zhǎng)期細(xì)胞,棄去培養(yǎng)液,PBS沖洗,加入離心管中,再加入1 ml RIPA裂解液置于冰浴上裂解30 min,4 ℃條件下離心15 min,BCA蛋白濃度試劑盒檢測(cè)蛋白純度。將20 μg蛋白提取液置于10%SDS- PAGE電泳分離,常規(guī)濕法轉(zhuǎn)膜,加入5%脫脂牛奶孵育封閉2 h。分別加入SPOCK1、mTOR、p- mTOR、S6K、p- S6K抗體,4 ℃孵育24 h。再滴加二抗37 ℃孵育2 h。PBS沖洗3次,按照ECL化學(xué)發(fā)光顯影試劑盒顯影,以GAPDH作為內(nèi)參照,分析目的條帶相對(duì)表達(dá)量。
采用SPSS 19.0軟件進(jìn)行數(shù)據(jù)處理,計(jì)量資料用均數(shù)±標(biāo)準(zhǔn)差表示,兩組間計(jì)量資料比較采用student’st檢驗(yàn),計(jì)數(shù)資料比較采用χ2檢驗(yàn)或fishers確切概率法;P<0.05表示差異有統(tǒng)計(jì)學(xué)意義。
轉(zhuǎn)染siSPOCK1后A549、H3255細(xì)胞SPOCK1蛋白表達(dá)明顯下調(diào)(圖1A),提示抑制SPOCK1表達(dá)肺癌細(xì)胞株構(gòu)建成功。MTT檢測(cè)結(jié)果顯示,A549、H3255細(xì)胞中siSPOCK1組細(xì)胞增殖率明顯低于NC組(P<0.05, 圖1B);細(xì)胞集落培養(yǎng)試驗(yàn)顯示,A549、H3255細(xì)胞中siSPOCK1組集落形成數(shù)明顯低于NC組(P<0.05, 圖1C、D)。細(xì)胞周期檢測(cè)結(jié)果顯示,在SPOCK1敲除的A549細(xì)胞中,siSPOCK1組和NC組G0/G1期細(xì)胞數(shù)分別為66.5%和54.3%,兩組間比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05,圖1E);在H3255細(xì)胞中,siSPOCK1組和NC組G0/G1期細(xì)胞數(shù)分別為70.2%和55.7%,兩組間比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05,圖1F)。
A.Western blotting檢測(cè)si- SPOCK1在A549、H3255細(xì)胞的轉(zhuǎn)染效率;B.MTT法檢測(cè)細(xì)胞增殖能力;C.集落培養(yǎng)實(shí)驗(yàn)檢測(cè)A549細(xì)胞集落形成情況;D.集落培養(yǎng)實(shí)驗(yàn)檢測(cè)H3255細(xì)胞集落形成情況;E.細(xì)胞周期分析A549細(xì)胞周期進(jìn)程;F.細(xì)胞周期分析H3255細(xì)胞周期進(jìn)程。與NC組比較,aP<0.01
圖1抑制SPOCK1表達(dá)對(duì)細(xì)胞增殖的影響
Fig1EffectsofinhibitiontheexpressionofSPOCK1onproliferationoflungcancercells
Transwell小室實(shí)驗(yàn)結(jié)果顯示,A549、H3255細(xì)胞中siSPOCK1組侵襲細(xì)胞數(shù)明顯少于NC組(P<0.05,圖2A);劃痕實(shí)驗(yàn)顯示,與NC組比較,siSPOCK1組劃痕愈合率明顯降低(P<0.05,圖2B)。
RT- PCR檢測(cè)結(jié)果顯示,A549、H3255細(xì)胞中,與NC組比較,siSPOCK1組mTOR、s6K mRNA表達(dá)水平明顯下降,組間比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05, 圖3A、C)。Western blotting檢測(cè)結(jié)果顯示,siSPOCK1組p- mTOR、p- s6K蛋白相對(duì)表達(dá)水平明顯低于NC組,兩組間比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05, 圖3B、D)。
肺癌早期癥狀不典型,大多數(shù)患者確診時(shí)已是中晚期,這亦是肺癌遠(yuǎn)期生存率不高的原因之一。因此從肺癌的發(fā)病機(jī)制中尋找到新的分子標(biāo)志物,對(duì)肺癌的分子靶向治療和早期診斷具有重要的臨床意義[3- 4]。SPOCK1是編碼細(xì)胞外基質(zhì)的重要蛋白多糖,既往研究發(fā)現(xiàn)SPOCK1主要參與調(diào)節(jié)中樞神經(jīng)系統(tǒng)、心血管系統(tǒng)的生物學(xué)過(guò)程[5]。基于SPOCK1在細(xì)胞- 基質(zhì)之間的調(diào)節(jié)作用,有學(xué)者認(rèn)為SPOCK1可能與腫瘤的侵襲、轉(zhuǎn)移等生物學(xué)行為有關(guān)[6- 7]。但是目前的多數(shù)報(bào)道僅為人體觀察或細(xì)胞行為研究,尚未見SPOCK1對(duì)肺癌作用的系統(tǒng)報(bào)道。
A.劃痕實(shí)驗(yàn)檢測(cè)細(xì)胞遷移能力;B.Transwell小室實(shí)驗(yàn)檢測(cè)細(xì)胞侵襲能力。與NC組比較,aP<0.01
圖2SPOCK1表達(dá)下調(diào)對(duì)肺癌細(xì)胞遷移、侵襲的影響
Fig2EffectsofinhibitiontheexpressionofSPOCK1onmigrationandinvasionoflungcancercells
A.RT- PCR檢測(cè)A549細(xì)胞mTOR、s6K mRNA表達(dá);B.Western blotting檢測(cè)A549細(xì)胞mTOR、p- mTOR、s6K、p- s6K蛋白表達(dá);C.RT- PCR檢測(cè)H3255細(xì)胞mTOR、s6K mRNA表達(dá);D.Western blotting檢測(cè)H3255細(xì)胞mTOR、p- mTOR、s6K、p- s6K蛋白表達(dá)。與NC組比較,aP<0.01
圖3SPOCK1表達(dá)下調(diào)對(duì)mTOR-S6K信號(hào)通路相關(guān)蛋白的影響
Fig3EffectsofinhibitiontheexpressionofSPOCK1onmTOR-S6Ksingnalingpathwayrelativeproteinoflungcancercells
本研究采用小干擾RNA(siRNA)技術(shù)抑制肺癌A549、H3255細(xì)胞SPOCK1的表達(dá),結(jié)果顯示A549、H3255細(xì)胞中siSPOCK1組細(xì)胞增殖率、集落形成數(shù)明顯低于NC組,說(shuō)明抑制SPOCK1表達(dá)能夠影響肺癌細(xì)胞的增殖。Song等[8]發(fā)現(xiàn)沉默SPOCK1基因的食管鱗癌細(xì)胞呈凋亡形態(tài),而陰性對(duì)照組細(xì)胞結(jié)構(gòu)均一、圓滑,間接證實(shí)SPOCK1可能促進(jìn)食管鱗癌細(xì)胞形成和抑制凋亡。SPOCK1調(diào)節(jié)細(xì)胞外基質(zhì)重構(gòu),導(dǎo)致正常細(xì)胞外基質(zhì)蛋白退化,這種細(xì)胞環(huán)境的改變有助于腫瘤細(xì)胞的惡性增生。本研究顯示,在SPOCK1敲除肺癌細(xì)胞中,siSPOCK1組G0/G1期細(xì)胞數(shù)明顯高于NC組,SPOCK1下調(diào)能夠抑制細(xì)胞G0至G1期的推進(jìn),說(shuō)明調(diào)節(jié)SPOCK1表達(dá)能夠調(diào)控細(xì)胞周期進(jìn)程。上皮間質(zhì)轉(zhuǎn)化(EMT)是介導(dǎo)腫瘤細(xì)胞侵襲、轉(zhuǎn)移的重要過(guò)程,Miao等[9]在研究肝癌細(xì)胞EMT時(shí)發(fā)現(xiàn),SPOCK1是TGF- β下游靶基因之一,TGF- β激活SPOCK1調(diào)節(jié)EMT的發(fā)生,使細(xì)胞獲得侵襲、遷移的能力。本研究也發(fā)現(xiàn)A549、H3255細(xì)胞中,siSPOCK1組侵襲細(xì)胞數(shù)、劃痕愈合率明顯低于NC組,說(shuō)明SPOCK1能夠介導(dǎo)肺癌細(xì)胞的侵襲、遷移等生物學(xué)行為。但是本研究尚無(wú)法證實(shí)這種行為是否與EMT有關(guān)。
關(guān)于SPOCK1對(duì)腫瘤細(xì)胞的調(diào)控機(jī)制,目前研究爭(zhēng)議較大。Zhang等[10]報(bào)道稱SPOCK1能夠激活PI3K/Akt信號(hào)通路促進(jìn)細(xì)胞的生長(zhǎng)和增殖,沉默SPOCK1基因能夠誘導(dǎo)Bax介導(dǎo)的凋亡信號(hào)通路調(diào)控細(xì)胞凋亡。Moshelion等[11]報(bào)道稱上調(diào)SPOCK1表達(dá),細(xì)胞Akt- Cyt C- caspase 3信號(hào)通路被激活,并抑制肝癌細(xì)胞的凋亡。mTOR- S6K信號(hào)通路是與腫瘤形成和進(jìn)展密切相關(guān)的一種信號(hào)通路,Tabatabaian等[12]報(bào)道稱激活mTOR、S6K基因可以影響腫瘤的增殖和凋亡抑制。Gobin等[13]也證實(shí)p53基因抑制骨肉瘤增殖是通過(guò)抑制mTOR- S6K信號(hào)通路實(shí)現(xiàn)的。本研究發(fā)現(xiàn)siSPOCK1組mTOR、s6K mRNA表達(dá)顯著低于NC組,siSPOCK1組p- mTOR、p- s6K蛋白相對(duì)表達(dá)水平明顯低于NC組,提示下調(diào)SPOCK1表達(dá)能夠抑制mTOR、S6K蛋白磷酸化。上述研究結(jié)果說(shuō)明SPOCK1可能是通過(guò)mTOR- S6K信號(hào)通路調(diào)節(jié)肺癌細(xì)胞的增殖、侵襲和遷移。
綜上所述,降低SPOCK1表達(dá)能夠抑制肺癌細(xì)胞增殖、侵襲和遷移能力,其作用機(jī)制可能與mTOR- s6K信號(hào)通路有關(guān)。
[1] 李龍,張紅,唐發(fā)兵,等.肺癌組織表皮生長(zhǎng)因子受體與RAS/MARK信號(hào)通路活化蛋白ERK1/2表達(dá)的相關(guān)性及其臨床意義[J].東南大學(xué)學(xué)報(bào):醫(yī)學(xué)版,2013,32(2):218- 221.
[2] 殷小偉,盧緒章,毛正道,等.肺癌細(xì)胞中NKG2D配體MICA及ULBP高表達(dá)及其在CIK介導(dǎo)的腫瘤細(xì)胞殺傷中的作用[J].東南大學(xué)學(xué)報(bào):醫(yī)學(xué)版,2016,35(6):861- 865.
[3] LI Y,CHEN L,CHAN T H,et al.SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice[J].Gastroenterology,2013,144(1):179- 191.
[4] 彭紅,韓寶惠,李小青,等.1279例肺癌患者臨床特征及生存率分析[J].中國(guó)癌癥雜志,2011,21(5):354- 358.
[5] 國(guó)昊楠,彭士云.SPOCK1蛋白結(jié)構(gòu)和功能與腫瘤的研究進(jìn)展[J].實(shí)用腫瘤學(xué)雜志,2015(4):380- 384.
[6] 畢丹丹,成秉林,葛瑞勝,等.SPOCK1的生物學(xué)研究進(jìn)展[J].醫(yī)學(xué)研究雜志,2016,45(5):180- 182,186.
[7] KUSAKABE M,KUTOMI T,WATANABE K,et al.Identification of G0S2 as a gene frequently methylated in squamous lung cancer by combination of in silico and experimental approaches[J].Int J Cancer,2010,126(8):1895- 1902.
[8] SONG X,HAN P,LIU J,et al.Up- regulation of SPOCK1 induces epithelial- mesenchymal transition and promotes migration and invasion in esophageal squamous cell carcinoma [J].J Mol Histol,2015,46(4- 5):347- 356.
[9] MIAO L,WANG Y,XIA H,et al.SPOCK1 is a novel transforming growth factor- β target gene that regulates lung cancer cell epithelial- mesenchymal transition[J].Biochem Biophys Res Commun,2013,440(4):792- 797.
[10] ZHANG Y,CHEN Q,ROSS A C.Retinoic acid and tumor necrosis factor- alpha induced monocytic cell gene expression is regulated in part by induction of transcription factor MafB[J].Exp Cell Res,2012,318(18):2407- 2416.
[11] MOSHELION M,BECKER D,CZEMPINSKI K,et al.Diurnal and circadian regulation of putative potassium channels in a leaf moving organ[J].Plant Physiol,2002,128(2):634- 642.
[12] TABATABAIAN F,DOUGHERTY K,di FULVIO M,et al.Mammalian target of rapamycin (mTOR) and S6 kinase down- regulate phospholipase D2 basal expression and function[J].J Biol Chem,2010,285(25):18991- 19001.
[13] GOBIN B,BATTAGLIA S,LANEL R,et al.NVP- BEZ235,a dual PI3K/mTOR inhibitor,inhibits osteosarcoma cell proliferation and tumor developmentinvivowith an improved survival rate[J].Cancer Lett,2014,344(2):291- 298.
SPOCK1promoteproliferation,invasionandmigrationoflungcancercellsthroughmTOR-s6Ksignalingpathway
PUJiang-tao,TANGXiao-jun,HUZhi,WUYun-fei,HEKai-ming,LIYuan,DAITian-yang
(DepartmentofThoracicandCardiovascularSurgery,theAffiliatedHospitalofSouthwestMedicalUniversity,Luzhou646000,China)
Objective: To explore the expression of SPOCK1 in lung cancer tissue and its effects on prolifetion, invasion and migration.MethodsLung cancer cell lines A549, H3255 were divided into interfere group and control group (NC group) according to interfection method, the expression of SPOCK1 in lung cancer cell line A549 and H3255 were inhibited by siRNA, the proliferation of cells were measured by MTT assay, the colony formation capacity were detected by colony formation assay, the migration capacity were mearsured by wound heal assay, the cell invasion capacity were mearsured by Transwelll assay, the expression of mRNA and protein related to mTOR- s6K pathway were measured by RT- PCR and Western blotting.ResultsIn A549 and H3255 cell lines, the cell proliferation rate, number of colonies, number of invasion cells, wound healing rates in siSPOCK1 group were significantly less than those in NC group, the difference were statistically significant (P<0.05). In SPOCK1 knockdown A549 cells, the G0/G1phases cell were 66.5% and 54.3% in siSPOCK1 and NC group, respectively, the difference between the two groups was statistically significant (P<0.05). And in H3255 cells, the G0/G1phases cell were 70.2% and 55.7% in siSPOCK1 and NC group, respectively, the difference between the two groups was statistically significant (P<0.05). In A549 and H3255 cell linse, the expression of mTOR, s6K mRNA in siSPOCK1 group was statistically decreased when compared to NC group, the difference between the two groups was statistically significant (P<0.05).The expression of p- mTOR, p- s6K protein in siSPOCK1 group were statistically decreased when compared to NC group, the difference between the two groups was statistically significant (P<0.05).ConclusionInhibition the expression of SPOCK1 can reduce the proliferation, invasion and migration capability of lung cancer cells, and its mechanism may be related to mTOR- s6K signaling pathway.
SPOCK1; lung cancer; proliferation; invasion; migration; mTOR- s6K signaling pathway
2017- 02- 21
2017- 07- 01
蒲江濤(1972-),男,四川巴中人,副教授,醫(yī)學(xué)碩士。E- mail:pujiangtao72@sina.com
蒲江濤,唐小軍,胡智,等. SPOCK1通過(guò)mTOR- s6K信號(hào)通路誘導(dǎo)肺癌細(xì)胞增殖、侵襲和遷移[J].東南大學(xué)學(xué)報(bào):醫(yī)學(xué)版,2017,36(5):746- 752.
R734.2
A
1671- 6264(2017)05- 0746- 07
10.3969/j.issn.1671- 6264.2017.05.012
(本文編輯:何彥梅)